BGB-16673 - BTK-Degrader in combination for Relapsed or Refractory B-Cell Malignancies - Mater Research

Unsupported browser

The browser you are using to browse this website is outdated and some features may not display properly or be accessible to you. Please use a more recent browser for the best user experience.

Latest news Contact us

Go to homepage Support us

Back to all Current clinical trials

BGB-16673 - BTK-Degrader in combination for Relapsed or Refractory B-Cell Malignancies

First in human study looking at treating B-Cell malignancies with an oral drug that works with BTK inhibitors to improve their effectiveness even after failure to with prior treatment of BTK inhibitors.

Category
Medical
Trial status
Active, not recruiting
Trial phase
Phase 1 Drug Trial
Early stage studies seeking initial evidence of safety, dosage and efficacy in small numbers of patients or healthy volunteers.
ERM Project ID
112145

Trial contact details

Contact person
Chris McKeon
Email
Medical.Trials@mater.org.au
Phone
07 3163 6694

What you need to know

Who can take part?

Main Inclusions

B-Cell malignancies
Measurable disease
Life expectancy > 6 months
Adequate organ function
Main Exclusions
treatment naive B-Cell malignancy
Inability to comply with protocol
Untreated brain metastasis
Autologous stem cell transplant or CART < 3months
active infections

What is involved for me?

Oral treatment with 2 drugs.
Weekly clinic visits for first 2 months then monthly for 3 then every 3 months.
Regular PET/CT/MRI scans

Back to all Current clinical trials

All research clinical trials news

View all news